E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The approval expands the use of the IL-23 inhibitor, previously approved for moderate-to-severe plaque psoriasis, to adults with active psoriatic arthritis.
imphoenix82
Under its agreement with the US government, Sun Pharma will extend Most Favoured Nation (MFN) pricing to state Medicaid programmes and apply MFN pricing to future innovative medicine launches.
imphoenix82
Under a licensing agreement signed with Philogen in May 2023, Sun Pharma holds exclusive commercialization rights for Nidlegy in Europe, Australia and New Zealand for the treatment of skin cancers.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
